Dr. Burris on Treatment Considerations in TNBC

In Partnership With:

Partner | Cancer Centers | <b>Sarah Cannon Research Institute at Tennessee Oncology</b>

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​treatment considerations in triple-negative breast cancer.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, chief medical officer and president of Clinical Operations at Sarah Cannon Research Institute, 2019-2020 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses ​treatment considerations in triple-negative breast cancer (TNBC).

Patients with TNBC should be considered for clinical trials, says Burris. Notably, several emerging agents are showing encouraging data in the relapsed/refractory setting.

Moreover, it’s of critical importance for this group of patients to undergo molecular profiling because it can help identify BRCA or DNA damage repair mutations, high tumor mutational burden, or PD-L1 overexpression.

​Additionally, molecular information can inform therapy selection; thus, patients are encouraged to undergo molecular profiling, Burris concludes.